Literature DB >> 10393185

The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor hDaxx.

A D Hollenbach1, J E Sublett, C J McPherson, G Grosveld.   

Abstract

The Pax3-FKHR fusion protein is present in alveolar rhabdomyosarcoma and results from the t(2;13) (q35;q14) chromosomal translocation. Its oncogenic activity is dependent on a combination of protein-DNA and protein-protein interactions mediated by the Pax3 homeodomain recognition helix. In this report we demonstrate that human Daxx (hDaxx) interacts with Pax3 in vivo and with DNA-bound Pax3 in vitro. This interaction is mediated primarily through the homeodomain recognition helix with the additional involvement of the octapeptide domain and its N-terminal flanking amino acids. Through this interaction hDaxx represses the transcriptional activity of Pax3 by approximately 80%. The Pax3-FKHR fusion is unresponsive to this repressive effect despite an observed endogenous interaction with hDaxx in a rhabdomyosarcoma tumor cell line. Therefore, these data support the model that fusion of FKHR to Pax3 not only adds a strong transactivation domain, but also deregulates transcriptional control of Pax3 by overriding the natural repressive effect of hDaxx.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393185      PMCID: PMC1171447          DOI: 10.1093/emboj/18.13.3702

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  74 in total

1.  Transcriptional repression by Pax5 (BSAP) through interaction with corepressors of the Groucho family.

Authors:  D Eberhard; G Jiménez; B Heavey; M Busslinger
Journal:  EMBO J       Date:  2000-05-15       Impact factor: 11.598

2.  MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.

Authors:  Chi Wai So; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

3.  The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.

Authors:  Yutong Xue; Richard Gibbons; Zhijiang Yan; Dafeng Yang; Tarra L McDowell; Salvatore Sechi; Jun Qin; Sharleen Zhou; Doug Higgs; Weidong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-02       Impact factor: 11.205

4.  Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirus-infected cells.

Authors:  Sabrina Schreiner; Peter Wimmer; Hüseyin Sirma; Roger D Everett; Paola Blanchette; Peter Groitl; Thomas Dobner
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

5.  FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Authors:  Lisa E S Crose; Katherine T Etheridge; Candy Chen; Brian Belyea; Lindsay J Talbot; Rex C Bentley; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

6.  Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL.

Authors:  C Raoul; E Buhler; C Sadeghi; A Jacquier; P Aebischer; B Pettmann; C E Henderson; G Haase
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-31       Impact factor: 11.205

7.  Negative modulation of androgen receptor transcriptional activity by Daxx.

Authors:  Ding-Yen Lin; Hsin-I Fang; Ai-Hong Ma; Yen-Sung Huang; Yeong-Shiau Pu; Guido Jenster; Hsing-Jien Kung; Hsiu-Ming Shih
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

8.  Daxx silencing sensitizes cells to multiple apoptotic pathways.

Authors:  Liuh-Yow Chen; J Don Chen
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

9.  Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors.

Authors:  Irina Lagutina; Simon J Conway; Jack Sublett; Gerard C Grosveld
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

10.  Retroviral DNA methylation and epigenetic repression are mediated by the antiviral host protein Daxx.

Authors:  Natalia Shalginskikh; Andrey Poleshko; Anna Marie Skalka; Richard A Katz
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.